The Art of Process Chemistry - Hardcover

Über die Autorin bzw. den Autor

Nobuyoshi Yasuda received his bachelor from Tokyo Institute of Technology under the direction of Professor Teruaki Mukaiyama and Professor Hisashi Takei and his mater degree from the same university under the direction of Professor Hisashi Takei. After working at Fujisawa Pharmaceutical Company, Japan as a Medicinal Chemist, he received Ph. D. from Tokyo Institute of Technology in 1987. After spend one year as a postdoctoral fellow under Professor Robert M. Williams at Colorado State University from 1988 to 1989, he joined in Process Chemistry, Merck Research Laboratories in 1990. He has over 60 publications and over 50 patents.

Von der hinteren Coverseite

The refinement of a chemical process to the point where it becomes both cost and time efficient can be seen as "art." In a competitive environment where pharmaceutical companies are under ever increasing pressure to bring new drugs more quickly to the market, ways need to be found to provide bulk supplies of drug candidates as quickly as possible and to design manufacturing routes, which are robust, economical and environmentally firendly. This monograph is divided into 9 chapters, each one concentrating on a single class of drug candidates of chemistry development and describing the routes explored and the optimizations made to each drug candidate, inluding the discovery of applicable new chemistry and the elucidation of reaction mechanism.

From the contents:

• Efairenz®, a Non-Nucleoside Reverse Transciptase Inhibitor (NNRTI), and a Previous Structurally Related Development Candidate
• CCR5 Receptor Antagonist
• 5α-Reductase Inhibitors – The Finsteride Story
• Rizatriptan (Maxalt®): A 5-HT1D Receptor Agonist
• SERM: Selective Estrogen Receptor Modulator
• HIV Integrase Inhibitor: Raltegravir
• Cyclopentane-Based NK1 Receptor Antagonist
• Glucokinase Activator
• CB1R Inverse Agonist – Taranabant

Aus dem Klappentext

The refinement of a chemical process to the point where it becomes both cost and time efficient can be seen as "art." In a competitive environment where pharmaceutical companies are under ever increasing pressure to bring new drugs more quickly to the market, ways need to be found to provide bulk supplies of drug candidates as quickly as possible and to design manufacturing routes, which are robust, economical and environmentally firendly. This monograph is divided into 9 chapters, each one concentrating on a single class of drug candidates of chemistry development and describing the routes explored and the optimizations made to each drug candidate, inluding the discovery of applicable new chemistry and the elucidation of reaction mechanism.

From the contents:

• Efairenz^®, a Non-Nucleoside Reverse Transciptase Inhibitor (NNRTI), and a Previous Structurally Related Development Candidate
• CCR5 Receptor Antagonist
• 5α-Reductase Inhibitors – The Finsteride Story
• Rizatriptan (Maxalt^®): A 5-HT1D Receptor Agonist
• SERM: Selective Estrogen Receptor Modulator
• HIV Integrase Inhibitor: Raltegravir
• Cyclopentane-Based NK1 Receptor Antagonist
• Glucokinase Activator
• CB1R Inverse Agonist – Taranabant